Open AccessTreatment options in pulmonary arterial hypertension
Author(s) -
Toshner Mark
Publication year - 2007
Publication title -
future prescriber
Language(s) - English
Resource type - Journals
eISSN - 1931-2261
pISSN - 1468-9871
DOI - 10.1002/fps.29
Subject(s) - medicine , thickening , pulmonary hypertension , cardiology , life expectancy , heart failure , population , chemistry , environmental health , polymer science
Pulmonary arterial hypertension (PAH) is a rare, severe and progressive disease characterised by raised pressures in the arteries in the lungs leading to right heart failure and, historically, a median life expectancy of 2.8 years with‐out targeted treatment. 1 Pathologically, it is characterised by a thickening of the muscular layer of the arteries, dysfunction of the vessel walls, and abnormal growth of supporting cells such as fibroblasts. Copyright © 2007 Wiley Interface Ltd